U.S. ramps up pharmaceutical oversight in China, FDA official testifies

04/4/2014 | Reuters · Bloomberg

Chinese makers of pharmaceutical ingredients are coming under increasing scrutiny from the U.S. FDA in an effort to bolster the safety of the U.S. drug supply chain, Christopher Hickey, director of the FDA's office in China, said Thursday at a hearing in Washington. The process of adding inspectors and staff in China has started on the back of the FDA's new legal authority and additional funding, he said. "As the number of medical products coming from China has increased, so have the challenges," he told the U.S.-China Economic and Security Review Commission.

View Full Article in:

Reuters · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ